KDR and hepatocellular carcinoma: Sorafenib primarily suppresses the growth and angiogenesis of HCC cells by targeting and inhibiting vascular endothelial growth factor receptors (VEGFR) as well as the Raf/MEK/ERK signaling pathway (Jiang et al., 2023).